Within the last few years, several new and novel FDA-approved treatments have become available for HCC, offering hope to patients with advances disease who are not candidates for curative surgeries. AGA’s newest guideline provides you with the most up-to-date guidance on how to use these new therapies in your practice.
The guidelines were developed to not only guide hepatologists through care and treatment of their HCC patients, but also to highlight the importance of consulting a multidisciplinary team of health care professionals — including radiologists and oncologists — when developing a treatment plan.
Top guideline recommendations
- Systemic therapies are only recommended for patients with advanced HCC not amenable to surgical or radiological treatment but with preserved liver function. First line treatments include atezolizumab/bevacizumab, sorafenib, and lenvatinib with atezolizumab/bevacizumab showing modest improvement over sorafenib and thus considered first.
- Recommendations were made for cabozantinib, pembrolizumab, ramucirumab, and regorafenib recognizing that this is an area of great limitation with likely more data in future studies.
- Systemic therapy are not recommended for patients with poor liver function.
- Systemic therapy are not recommended as adjuvant therapy for HCC.
Read the AGA Clinical Practice Guidelines on Systemic Therapy for Hepatocellular Carcinoma to review all 11 recommendations that detail specific patient scenarios and best treatment options.
